Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...
Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback